<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Antidepressants: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i229.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i229.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i229.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i228.htm" title="Previous: Tinzaparin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1145.htm" title="Next: Agomelatine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i229">Antidepressants</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Antidepressants</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  antidepressants advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i1009.htm" name="_1009">Atomoxetine</a></td><td>possible increased risk of convulsions when  antidepressants given with atomoxetine </td><td></td></tr></tbody></table><p><b>Agomelatine</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td class="cBV"><b>manufacturer of  agomelatine advises avoid concomitant use with ciprofloxacin </b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>metabolism of  agomelatine inhibited by fluvoxamine (increased plasma concentration)</b></td><td></td></tr></tbody></table><p><b>Mirtazapine</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>














<tr><td><a href="41001i20.htm">Alcohol</a></td><td class="cBV"><b>increased sedative effect when  mirtazapine given with alcohol </b></td><td></td></tr><tr><td><a href="41001i404.htm">Anxiolytics and Hypnotics</a></td><td>increased sedative effect when  mirtazapine given with anxiolytics and hypnotics </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  mirtazapine reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  mirtazapine increased by cimetidine </td><td></td></tr><tr><td><a href="41001i482.htm">Clonidine</a></td><td> mirtazapine possibly antagonises hypotensive effect of clonidine </td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td>possible increased serotonergic effects when  mirtazapine given with fluoxetine </td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td>possible increased serotonergic effects when  mirtazapine given with fluvoxamine </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of  mirtazapine increased by ketoconazole </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> mirtazapine should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 2 weeks after stopping mirtazapine</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  mirtazapine do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  mirtazapine reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i106.htm">Tramadol</a></td><td>possible increased serotonergic effects when  mirtazapine given with tramadol </td><td></td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td>possible increased serotonergic effects when  mirtazapine given with venlafaxine </td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td> mirtazapine enhances anticoagulant effect of warfarin </td><td></td></tr></tbody></table><p><b>Antidepressants, Noradrenaline Re-uptake Inhibitors</b> belongs to
      <b>Antidepressants</b>
          but has no specific interaction information.
        </p><p><b>Reboxetine</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i293.htm">Antifungals, Imidazole</a></td><td class="cBV"><b>manufacturer of  reboxetine advises avoid concomitant use with imidazoles </b></td><td></td></tr><tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td class="cBV"><b>manufacturer of  reboxetine advises avoid concomitant use with triazoles </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  reboxetine possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td>possible increased risk of hypokalaemia when  reboxetine given with loop diuretics </td><td></td></tr><tr><td><a href="41001i525.htm">Diuretics, Thiazide and related</a></td><td>possible increased risk of hypokalaemia when  reboxetine given with thiazides and related diuretics </td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td>possible risk of hypertension when  reboxetine given with ergotamine and methysergide </td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>manufacturer of  reboxetine advises avoid concomitant use with fluvoxamine </b></td><td></td></tr><tr><td><a href="41001i166.htm">Macrolides</a></td><td class="cBV"><b>manufacturer of  reboxetine advises avoid concomitant use with macrolides </b></td><td><i>See also</i> Telithromycin</td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  reboxetine given with MAOIs (MAOIs should not be started until 1 week after stopping reboxetine, avoid reboxetine for 2 weeks after stopping MAOIs)</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  reboxetine possibly reduced by phenobarbital </td><td></td></tr></tbody></table><p><b>Antidepressants, SSRI</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



















<tr><td><a href="41001i20.htm">Alcohol</a></td><td>sedative effects possibly increased when  SSRIs given with alcohol </td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b> SSRIs increase plasma concentration of some tricyclics </b></td><td></td></tr><tr><td><a href="41001i276.htm">Antiepileptics</a></td><td class="cBV"><b> SSRIs antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i361.htm">Aspirin</a></td><td class="cBV"><b>increased risk of bleeding when  SSRIs given with aspirin </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> SSRIs possibly enhance anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i317.htm">Cyproheptadine</a></td><td>antidepressant effect of  SSRIs possibly antagonised by cyproheptadine </td><td></td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td>possible increased serotonergic effects when  SSRIs given with duloxetine </td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td class="cBV"><b>Increased risk of CNS effects when  SSRIs given with lithium (lithium toxicity reported)</b></td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>CNS effects of  SSRIs increased by MAOIs (risk of serious toxicity)</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i718.htm">Methylphenidate</a></td><td>metabolism of  SSRIs possibly inhibited by methylphenidate </td><td></td></tr><tr><td><a href="41001i613.htm">Metoclopramide</a></td><td>CNS toxicity reported when  SSRIs given with metoclopramide </td><td></td></tr><tr><td><a href="41001i573.htm">Naratriptan</a></td><td>possible increased serotonergic effects when  SSRIs given with naratriptan </td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>increased risk of bleeding when  SSRIs given with NSAIDs </b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b> SSRIs possibly increase plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b>increased risk of CNS toxicity when  SSRIs given with rasagiline </b></td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  SSRIs possibly increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>increased serotonergic effects when  SSRIs given with St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i106.htm">Tramadol</a></td><td class="cBV"><b>increased risk of CNS toxicity when  SSRIs given with tramadol </b></td><td></td></tr><tr><td><a href="41001i263.htm">Tryptophan</a></td><td class="cBV"><b>agitation and nausea may occur when  SSRIs given with tryptophan </b></td><td></td></tr></tbody></table><p><b>Escitalopram</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  escitalopram increased by cimetidine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> escitalopram should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 1 week after stopping escitalopram</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td> escitalopram increases plasma concentration of metoprolol </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>increased risk of CNS toxicity when  escitalopram given with moclobemide , preferably avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td>plasma concentration of  escitalopram increased by omeprazole </td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td>avoidance of  escitalopram advised by manufacturer of selegiline </td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>increased risk of CNS toxicity when  escitalopram given with sumatriptan </b></td><td></td></tr></tbody></table><p><b>Citalopram</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i572.htm">5HT<sub>1</sub>-receptor Agonists</a></td><td class="cBV"><b>increased risk of CNS toxicity when  citalopram given with 5HT<sub>1</sub> agonists (manufacturer of citalopram advises avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i896.htm">Bupropion</a></td><td>plasma concentration of  citalopram possibly increased by bupropion </td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  citalopram increased by cimetidine </td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td> citalopram possibly increases plasma concentration of clozapine (increased risk of toxicity)</td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> citalopram should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 1 week after stopping citalopram</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td> citalopram increases plasma concentration of metoprolol </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  citalopram do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td>avoidance of  citalopram advised by manufacturer of selegiline </td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>increased risk of CNS toxicity when  citalopram given with sumatriptan </b></td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td>possible increased risk of bleeding when  citalopram given with ticagrelor </td><td></td></tr></tbody></table><p><b>Fluoxetine</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





















<tr><td><a href="41001i406.htm">Alprazolam</a></td><td> fluoxetine increases plasma concentration of alprazolam </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> fluoxetine possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td> fluoxetine possibly inhibits metabolism of atomoxetine </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> fluoxetine increases plasma concentration of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> fluoxetine possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b> fluoxetine increases plasma concentration of clozapine </b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>avoidance of  fluoxetine advised by manufacturer of droperidol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td> fluoxetine increases plasma concentration of flecainide </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b> fluoxetine increases plasma concentration of haloperidol </b></td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> fluoxetine should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 5 weeks after stopping fluoxetine</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> fluoxetine possibly increases plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td>possible increased serotonergic effects when  fluoxetine given with mirtazapine </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  fluoxetine do not start moclobemide for 5 weeks</b></td><td></td></tr><tr><td><a href="41001i475.htm">Nifedipine</a></td><td> fluoxetine possibly inhibits metabolism of nifedipine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> fluoxetine increases plasma concentration of phenytoin </b></td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b> fluoxetine should not be started until 2 weeks after stopping rasagiline , also rasagiline should not be started until at least 5 weeks after stopping fluoxetine</b></td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i368.htm">Risperidone</a></td><td> fluoxetine increases plasma concentration of risperidone </td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  fluoxetine given with selegiline (selegiline should not be started until 5 weeks after stopping fluoxetine, avoid fluoxetine for 2 weeks after stopping selegiline)</b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>increased risk of CNS toxicity when  fluoxetine given with sumatriptan </b></td><td></td></tr><tr><td><a href="41001i581.htm">Tamoxifen</a></td><td class="cBV"><b> fluoxetine possibly inhibits metabolism of tamoxifen to active metabolite (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i263.htm">Tryptophan</a></td><td>CNS toxicity reported when  fluoxetine given with tryptophan </td><td></td></tr></tbody></table><p><b>Fluvoxamine</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




























<tr><td><a href="41001i1145.htm">Agomelatine</a></td><td class="cBV"><b> fluvoxamine inhibits metabolism of agomelatine (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1209.htm">Asenapine</a></td><td> fluvoxamine possibly increases plasma concentration of asenapine </td><td></td></tr><tr><td><a href="41001i405.htm">Benzodiazepines</a></td><td> fluvoxamine increases plasma concentration of some benzodiazepines </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> fluvoxamine increases plasma concentration of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> fluvoxamine possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b> fluvoxamine increases plasma concentration of clozapine </b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>avoidance of  fluvoxamine advised by manufacturer of droperidol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td class="cBV"><b> fluvoxamine inhibits metabolism of duloxetine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i965.htm">Frovatriptan</a></td><td> fluvoxamine inhibits the metabolism of frovatriptan </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td> fluvoxamine possibly increases plasma concentration of haloperidol </td><td></td></tr><tr><td><a href="41001i753.htm">Lansoprazole</a></td><td> fluvoxamine possibly increases plasma concentration of lansoprazole </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> fluvoxamine should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 1 week after stopping fluvoxamine</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i1114.htm">Melatonin</a></td><td class="cBV"><b> fluvoxamine increases plasma concentration of melatonin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> fluvoxamine possibly increases plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td>possible increased serotonergic effects when  fluvoxamine given with mirtazapine </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  fluvoxamine do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i366.htm">Olanzapine</a></td><td> fluvoxamine increases plasma concentration of olanzapine </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> fluvoxamine increases plasma concentration of phenytoin </b></td><td></td></tr><tr><td><a href="41001i793.htm">Propranolol</a></td><td> fluvoxamine increases plasma concentration of propranolol </td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b> fluvoxamine should not be started until 2 weeks after stopping rasagiline </b></td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i231.htm">Reboxetine</a></td><td class="cBV"><b>avoidance of  fluvoxamine advised by manufacturer of reboxetine </b></td><td></td></tr><tr><td><a href="41001i1190.htm">Roflumilast</a></td><td> fluvoxamine inhibits the metabolism of roflumilast </td><td></td></tr><tr><td><a href="41001i888.htm">Ropivacaine</a></td><td> fluvoxamine inhibits metabolism of ropivacaine—avoid prolonged administration of ropivacaine</td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  fluvoxamine given with selegiline (selegiline should not be started until 1 week after stopping fluvoxamine, avoid fluvoxamine for 2 weeks after stopping selegiline)</b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>increased risk of CNS toxicity when  fluvoxamine given with sumatriptan </b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> fluvoxamine increases plasma concentration of theophylline (concomitant use should usually be avoided, but where not possible halve theophylline dose and monitor plasma-theophylline concentration)</b></td><td></td></tr><tr><td><a href="41001i805.htm">Tizanidine</a></td><td class="cBV"><b> fluvoxamine increases plasma concentration of tizanidine (increased risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i575.htm">Zolmitriptan</a></td><td> fluvoxamine possibly inhibits metabolism of zolmitriptan (reduce dose of zolmitriptan)</td><td></td></tr></tbody></table><p><b>Paroxetine</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>























<tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> paroxetine possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i1209.htm">Asenapine</a></td><td>plasma concentration of  paroxetine possibly increased by asenapine </td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td> paroxetine possibly inhibits metabolism of atomoxetine </td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b> paroxetine increases plasma concentration of clozapine </b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td> paroxetine increases plasma concentration of darifenacin </td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td>plasma concentration of  paroxetine possibly reduced by darunavir </td><td></td></tr><tr><td><a href="41001i915.htm">Galantamine</a></td><td> paroxetine increases plasma concentration of galantamine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> paroxetine should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 1 week after stopping paroxetine</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> paroxetine possibly increases plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td> paroxetine possibly increases plasma concentration of metoprolol (enhanced effect)</td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  paroxetine do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i381.htm">Perphenazine</a></td><td> paroxetine inhibits metabolism of perphenazine (reduce dose of perphenazine)</td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  paroxetine reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  paroxetine reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i354.htm">Procyclidine</a></td><td> paroxetine increases plasma concentration of procyclidine </td><td></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td> paroxetine possibly inhibits metabolism of propafenone (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td> paroxetine increases plasma concentration of ranolazine </td><td></td></tr><tr><td><a href="41001i368.htm">Risperidone</a></td><td> paroxetine possibly increases plasma concentration of risperidone (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  paroxetine possibly reduced by ritonavir </td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  paroxetine given with selegiline (selegiline should not be started until 2 weeks after stopping paroxetine, avoid paroxetine for 2 weeks after stopping selegiline)</b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>increased risk of CNS toxicity when  paroxetine given with sumatriptan </b></td><td></td></tr><tr><td><a href="41001i581.htm">Tamoxifen</a></td><td class="cBV"><b> paroxetine possibly inhibits metabolism of tamoxifen to active metabolite (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td>possible increased risk of bleeding when  paroxetine given with ticagrelor </td><td></td></tr></tbody></table><p><b>Sertraline</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>













<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  sertraline increased by cimetidine </td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b> sertraline increases plasma concentration of clozapine </b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td>plasma concentration of  sertraline possibly reduced by darunavir </td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>avoidance of  sertraline advised by manufacturer of droperidol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td>plasma concentration of  sertraline possibly increased by grapefruit juice </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> sertraline should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 1 week after stopping sertraline</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> sertraline possibly increases plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  sertraline do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  sertraline possibly reduced by phenytoin , also plasma concentration of phenytoin possibly increased</td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  sertraline given with selegiline (selegiline should not be started until 1 week after stopping sertraline, avoid sertraline for 2 weeks after stopping selegiline)</b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td>CNS toxicity reported when  sertraline given with sumatriptan </td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td>possible increased risk of bleeding when  sertraline given with ticagrelor </td><td></td></tr><tr><td><a href="41001i425.htm">Zolpidem</a></td><td>sedative effects possibly increased when  sertraline given with zolpidem </td><td></td></tr></tbody></table><p><b>Antidepressants, SSRI (related)</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  SSRI-related antidepressants do not start moclobemide for at least 1 week</b></td><td></td></tr></tbody></table><p><b>Duloxetine</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>













<tr><td><a href="41001i572.htm">5HT<sub>1</sub>-receptor Agonists</a></td><td>possible increased serotonergic effects when  duloxetine given with 5HT<sub>1</sub> agonists </td><td></td></tr><tr><td><a href="41001i242.htm">Amitriptyline</a></td><td>possible increased serotonergic effects when  duloxetine given with amitriptyline </td><td></td></tr><tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td>possible increased serotonergic effects when  duloxetine given with SSRIs </td><td></td></tr><tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td class="cBV"><b>metabolism of  duloxetine inhibited by ciprofloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i244.htm">Clomipramine</a></td><td>possible increased serotonergic effects when  duloxetine given with clomipramine </td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>metabolism of  duloxetine inhibited by fluvoxamine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> duloxetine should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 5 days after stopping duloxetine</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>possible increased serotonergic effects when  duloxetine given with moclobemide </b></td><td></td></tr><tr><td><a href="41001i102.htm">Pethidine</a></td><td>possible increased serotonergic effects when  duloxetine given with pethidine </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>possible increased serotonergic effects when  duloxetine given with St John's wort </td><td></td></tr><tr><td><a href="41001i106.htm">Tramadol</a></td><td>possible increased serotonergic effects when  duloxetine given with tramadol </td><td></td></tr><tr><td><a href="41001i263.htm">Tryptophan</a></td><td>possible increased serotonergic effects when  duloxetine given with tryptophan </td><td></td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td>possible increased serotonergic effects when  duloxetine given with venlafaxine </td><td></td></tr></tbody></table><p><b>Venlafaxine</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>














<tr><td><a href="41001i572.htm">5HT<sub>1</sub>-receptor Agonists</a></td><td>possible increased serotonergic effects when  venlafaxine given with 5HT<sub>1</sub> agonists </td><td></td></tr><tr><td><a href="41001i361.htm">Aspirin</a></td><td class="cBV"><b>increased risk of bleeding when  venlafaxine given with aspirin </b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b> venlafaxine increases plasma concentration of clozapine </b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td>possible increased serotonergic effects when  venlafaxine given with duloxetine </td><td></td></tr><tr><td><a href="41001i854.htm">Entacapone</a></td><td>caution with  venlafaxine advised by manufacturer of entacapone </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td> venlafaxine increases plasma concentration of haloperidol </td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>possible increased serotonergic effects when  venlafaxine given with lithium </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>enhanced CNS effects and toxicity when  venlafaxine given with MAOIs (venlafaxine should not be started until 2 weeks after stopping MAOIs, avoid MAOIs for 1 week after stopping venlafaxine)</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td>possible increased serotonergic effects when  venlafaxine given with mirtazapine </td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>increased risk of bleeding when  venlafaxine given with NSAIDs </b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  venlafaxine given with selegiline (selegiline should not be started until 1 week after stopping venlafaxine, avoid venlafaxine for 2 weeks after stopping selegiline)</b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>possible increased serotonergic effects when  venlafaxine given with St John's wort </td><td></td></tr><tr><td><a href="41001i106.htm">Tramadol</a></td><td>possible increased serotonergic effects when  venlafaxine given with tramadol </td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td class="cBV"><b> venlafaxine possibly enhances anticoagulant effect of warfarin </b></td><td></td></tr></tbody></table><p><b>Antidepressants, Tricyclic</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



























































<tr><td><a href="41001i715.htm">Adrenaline (epinephrine)</a></td><td class="cBV"><b>increased risk of hypertension and arrhythmias when  tricyclics given with adrenaline (epinephrine) (but local anaesthetics with adrenaline appear to be safe)</b></td><td></td></tr><tr><td><a href="41001i15.htm">Adrenergic Neurone Blockers</a></td><td> tricyclics antagonise hypotensive effect of adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i20.htm">Alcohol</a></td><td class="cBV"><b>increased sedative effect when  tricyclics given with alcohol </b></td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i39.htm">Anaesthetics, General</a></td><td>increased risk of arrhythmias and hypotension when  tricyclics given with general anaesthetics </td><td><i>See also</i> Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="6559.htm#_6559.1">section 15.1</a>



</td></tr><tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>plasma concentration of some  tricyclics increased by SSRIs </b></td><td></td></tr><tr><td><a href="41001i276.htm">Antiepileptics</a></td><td class="cBV"><b> tricyclics antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i303.htm">Antihistamines</a></td><td>increased antimuscarinic and sedative effects when  tricyclics given with antihistamines </td><td>Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)</td></tr><tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>increased risk of antimuscarinic side-effects when  tricyclics given with antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td class="cBV"><b>plasma concentration of  tricyclics increased by antipsychotics—possibly increased risk of ventricular arrhythmias</b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i404.htm">Anxiolytics and Hypnotics</a></td><td>increased sedative effect when  tricyclics given with anxiolytics and hypnotics </td><td></td></tr><tr><td><a href="41001i24.htm">Apraclonidine</a></td><td>avoidance of  tricyclics advised by manufacturer of apraclonidine </td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i617.htm">Baclofen</a></td><td> tricyclics enhance muscle relaxant effect of baclofen </td><td></td></tr><tr><td><a href="41001i25.htm">Brimonidine</a></td><td>avoidance of  tricyclics advised by manufacturer of brimonidine </td><td></td></tr><tr><td><a href="41001i896.htm">Bupropion</a></td><td>plasma concentration of  tricyclics possibly increased by bupropion (possible increased risk of convulsions)</td><td></td></tr><tr><td><a href="41001i1189.htm">Cannabis Extract</a></td><td>possible increased risk of hypertension and tachycardia when  tricyclics given with cannabis extract </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>metabolism of  tricyclics accelerated by carbamazepine (reduced plasma concentration and reduced effect)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  tricyclics possibly increased by cimetidine </td><td></td></tr><tr><td><a href="41001i482.htm">Clonidine</a></td><td class="cBV"><b> tricyclics antagonise hypotensive effect of clonidine , also increased risk of hypertension on clonidine withdrawal</b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td>possible increased antimuscarinic side-effects when  tricyclics given with clozapine </td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> tricyclics may enhance or reduce anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td>plasma concentration of  tricyclics possibly increased by diltiazem </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with disopyramide </b></td><td></td></tr><tr><td><a href="41001i523.htm">Disulfiram</a></td><td>metabolism of  tricyclics inhibited by disulfiram (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td>increased risk of postural hypotension when  tricyclics given with diuretics </td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  tricyclics advised by manufacturer of dronedarone (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>avoidance of  tricyclics advised by manufacturer of droperidol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i854.htm">Entacapone</a></td><td>caution with  tricyclics advised by manufacturer of entacapone </td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with flecainide </b></td><td></td></tr><tr><td><a href="41001i1180.htm">Histamine</a></td><td> tricyclics theoretically antagonise effects of histamine—manufacturer of histamine advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>risk of toxicity when  tricyclics given with lithium </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  tricyclics given with MAOIs , tricyclics should not be started until 2 weeks after stopping MAOIs (3 weeks if starting clomipramine or imipramine), also MAOIs should not be started for at least 1–2 weeks after stopping tricyclics (3 weeks in the case of clomipramine or imipramine)</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i718.htm">Methylphenidate</a></td><td>metabolism of  tricyclics possibly inhibited by methylphenidate </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  tricyclics do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i615.htm">Moxonidine</a></td><td> tricyclics possibly antagonise hypotensive effect of moxonidine (manufacturer of moxonidine advises avoid concomitant use)</td><td></td></tr><tr><td><a href="41001i58.htm">Nefopam</a></td><td>side-effects possibly increased when  tricyclics given with nefopam </td><td></td></tr><tr><td><a href="41001i630.htm">Nicorandil</a></td><td> tricyclics possibly enhance hypotensive effect of nicorandil </td><td></td></tr><tr><td><a href="41001i631.htm">Nitrates</a></td><td> tricyclics reduce effects of sublingual tablets of nitrates (failure to dissolve under tongue owing to dry mouth)</td><td></td></tr><tr><td><a href="41001i711.htm">Noradrenaline (norepinephrine)</a></td><td class="cBV"><b>increased risk of hypertension and arrhythmias when  tricyclics given with noradrenaline (norepinephrine) </b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>antidepressant effect of  tricyclics antagonised by oestrogens (but side-effects of tricyclics  possibly increased due to increased plasma concentration)</td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i85.htm">Opioid Analgesics</a></td><td>sedative effects possibly increased when  tricyclics given with opioid analgesics </td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with pentamidine isetionate </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>metabolism of  tricyclics possibly accelerated by phenobarbital (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i373.htm">Phenothiazines</a></td><td>increased risk of antimuscarinic side-effects when  tricyclics given with phenothiazines </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  tricyclics possibly reduced by phenytoin </b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td class="cBV"><b>increased risk of arrhythmias when  tricyclics given with propafenone </b></td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b>increased risk of CNS toxicity when  tricyclics given with rasagiline </b></td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  tricyclics possibly increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>CNS toxicity reported when  tricyclics given with selegiline </b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i1067.htm">Sodium Oxybate</a></td><td>increased risk of side-effects when  tricyclics given with sodium oxybate </td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with sotalol </b></td><td></td></tr><tr><td><a href="41001i292.htm">Terbinafine</a></td><td>plasma concentration of  tricyclics possibly increased by terbinafine </td><td></td></tr><tr><td><a href="41001i935.htm">Thyroid Hormones</a></td><td>effects of  tricyclics possibly enhanced by thyroid hormones </td><td></td></tr><tr><td><a href="41001i106.htm">Tramadol</a></td><td class="cBV"><b>increased risk of CNS toxicity when  tricyclics given with tramadol </b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td>plasma concentration of  tricyclics possibly increased by verapamil </td><td></td></tr></tbody></table><p><b>Amitriptyline</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i1168.htm">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  amitriptyline given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  amitriptyline inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i523.htm">Disulfiram</a></td><td>concomitant  amitriptyline reported to increase disulfiram reaction with alcohol</td><td></td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td>possible increased serotonergic effects when  amitriptyline given with duloxetine </td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  amitriptyline possibly increased by fluconazole </td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>plasma concentration of  amitriptyline reduced by St John's wort </td><td></td></tr><tr><td><a href="41001i935.htm">Thyroid Hormones</a></td><td>effects of  amitriptyline enhanced by thyroid hormones </td><td></td></tr></tbody></table><p><b>Clomipramine</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i1168.htm">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  clomipramine given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td>possible increased serotonergic effects when  clomipramine given with duloxetine </td><td></td></tr></tbody></table><p><b>Dosulepin</b> belongs to
      <b>Antidepressants</b>
          but has no specific interaction information.
        </p><p><b>Doxepin</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  doxepin inhibited by cimetidine (increased plasma concentration)</td><td></td></tr></tbody></table><p><b>Imipramine</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  imipramine inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td>plasma concentration of  imipramine increased by diltiazem </td><td></td></tr><tr><td><a href="41001i448.htm">Labetalol</a></td><td>plasma concentration of  imipramine increased by labetalol </td><td></td></tr><tr><td><a href="41001i793.htm">Propranolol</a></td><td>plasma concentration of  imipramine increased by propranolol </td><td></td></tr><tr><td><a href="41001i935.htm">Thyroid Hormones</a></td><td>effects of  imipramine enhanced by thyroid hormones </td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td>plasma concentration of  imipramine increased by verapamil </td><td></td></tr></tbody></table><p><b>Lofepramine</b> belongs to
      <b>Antidepressants</b>
          but has no specific interaction information.
        </p><p><b>Nortriptyline</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  nortriptyline inhibited by cimetidine (increased plasma concentration)</td><td></td></tr></tbody></table><p><b>Trimipramine</b> belongs to
      <b>Antidepressants</b>
          but has no specific interaction information.
        </p><p><b>Antidepressants, Tricyclic (related)</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>













<tr><td><a href="41001i20.htm">Alcohol</a></td><td class="cBV"><b>increased sedative effect when  tricyclic-related antidepressants given with alcohol </b></td><td></td></tr><tr><td><a href="41001i276.htm">Antiepileptics</a></td><td class="cBV"><b> tricyclic-related antidepressants possibly antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i303.htm">Antihistamines</a></td><td>possible increased antimuscarinic and sedative effects when  tricyclic-related antidepressants given with antihistamines </td><td>Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)</td></tr><tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>possible increased antimuscarinic side-effects when  tricyclic-related antidepressants given with antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i404.htm">Anxiolytics and Hypnotics</a></td><td>increased sedative effect when  tricyclic-related antidepressants given with anxiolytics and hypnotics </td><td></td></tr><tr><td><a href="41001i24.htm">Apraclonidine</a></td><td>avoidance of  tricyclic-related antidepressants advised by manufacturer of apraclonidine </td><td></td></tr><tr><td><a href="41001i25.htm">Brimonidine</a></td><td>avoidance of  tricyclic-related antidepressants advised by manufacturer of brimonidine </td><td></td></tr><tr><td><a href="41001i522.htm">Diazoxide</a></td><td>enhanced hypotensive effect when  tricyclic-related antidepressants given with diazoxide </td><td></td></tr><tr><td><a href="41001i763.htm">Hydralazine</a></td><td>enhanced hypotensive effect when  tricyclic-related antidepressants given with hydralazine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> tricyclic-related antidepressants should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 1–2 weeks after stopping tricyclic-related antidepressants</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  tricyclic-related antidepressants do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i631.htm">Nitrates</a></td><td> tricyclic-related antidepressants possibly reduce effects of sublingual tablets of nitrates (failure to dissolve under tongue owing to dry mouth)</td><td></td></tr><tr><td><a href="41001i765.htm">Sodium Nitroprusside</a></td><td>enhanced hypotensive effect when  tricyclic-related antidepressants given with sodium nitroprusside </td><td></td></tr></tbody></table><p><b>Mianserin</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  mianserin reduced by carbamazepine </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>metabolism of  mianserin accelerated by phenobarbital (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  mianserin reduced by phenytoin </b></td><td></td></tr></tbody></table><p><b>Trazodone</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  trazodone reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td>plasma concentration of  trazodone possibly increased by clarithromycin </td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  trazodone increased by ritonavir (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  trazodone given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td>plasma concentration of  trazodone possibly increased by telaprevir </td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td> trazodone may enhance or reduce anticoagulant effect of warfarin </td><td></td></tr></tbody></table><p><b>MAOIs</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><div>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



































































<tr><td><a href="41001i2.htm">ACE Inhibitors</a></td><td> MAOIs possibly enhance hypotensive effect of ACE inhibitors </td><td></td></tr><tr><td><a href="41001i15.htm">Adrenergic Neurone Blockers</a></td><td>enhanced hypotensive effect when  MAOIs given with adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i20.htm">Alcohol</a></td><td class="cBV"><b> MAOIs interact with tyramine found in some beverages containing alcohol and some dealcoholised beverages (hypertensive crisis)—if no tyramine, enhanced hypotensive effect</b></td><td></td></tr><tr><td><a href="41001i26.htm">Alpha-blockers</a></td><td>enhanced hypotensive effect when  MAOIs given with alpha-blockers </td><td></td></tr><tr><td><a href="41001i107.htm">Angiotensin-II Receptor Antagonists</a></td><td> MAOIs possibly enhance hypotensive effect of angiotensin-II receptor antagonists </td><td></td></tr><tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b> MAOIs increase CNS effects of SSRIs (risk of serious toxicity)</b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  MAOIs given with tricyclics , tricyclics should not be started until 2 weeks after stopping MAOIs (3 weeks if starting clomipramine or imipramine), also MAOIs should not be started for at least 1–2 weeks after stopping tricyclics (3 weeks in the case of clomipramine or imipramine)</b></td><td></td></tr><tr><td><a href="41001i252.htm">Antidepressants, Tricyclic (related)</a></td><td class="cBV"><b>after stopping  MAOIs do not start tricyclic-related antidepressants for 2 weeks, also MAOIs should not be started until at least 1–2 weeks after stopping tricyclic-related antidepressants</b></td><td></td></tr><tr><td><a href="41001i264.htm">Antidiabetics</a></td><td> MAOIs possibly enhance hypoglycaemic effect of antidiabetics </td><td></td></tr><tr><td><a href="41001i276.htm">Antiepileptics</a></td><td> MAOIs possibly antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered)</td><td></td></tr><tr><td><a href="41001i303.htm">Antihistamines</a></td><td>increased antimuscarinic and sedative effects when  MAOIs given with antihistamines </td><td>Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)</td></tr><tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>increased risk of antimuscarinic side-effects when  MAOIs given with antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i24.htm">Apraclonidine</a></td><td>avoidance of  MAOIs advised by manufacturer of apraclonidine </td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td class="cBV"><b>after stopping  MAOIs do not start atomoxetine for 2 weeks, also MAOIs should not be started until at least 2 weeks after stopping atomoxetine</b></td><td></td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td>enhanced hypotensive effect when  MAOIs given with beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i25.htm">Brimonidine</a></td><td>avoidance of  MAOIs advised by manufacturer of brimonidine </td><td></td></tr><tr><td><a href="41001i896.htm">Bupropion</a></td><td class="cBV"><b>avoidance of bupropion for 2 weeks after stopping  MAOIs advised by manufacturer of bupropion </b></td><td></td></tr><tr><td><a href="41001i427.htm">Buspirone</a></td><td>avoidance of  MAOIs advised by manufacturer of buspirone </td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td>enhanced hypotensive effect when  MAOIs given with calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>avoidance for 2 weeks after stopping  MAOIs advised by manufacturer of carbamazepine , also antagonism of anticonvulsant effect</b></td><td></td></tr><tr><td><a href="41001i233.htm">Citalopram</a></td><td class="cBV"><b>after stopping  MAOIs do not start citalopram for 2 weeks, also MAOIs should not be started until at least 1 week after stopping citalopram</b></td><td></td></tr><tr><td><a href="41001i482.htm">Clonidine</a></td><td>enhanced hypotensive effect when  MAOIs given with clonidine </td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>CNS effects of  MAOIs possibly increased by clozapine </b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i522.htm">Diazoxide</a></td><td>enhanced hypotensive effect when  MAOIs given with diazoxide </td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td>enhanced hypotensive effect when  MAOIs given with diuretics </td><td></td></tr><tr><td><a href="41001i561.htm">Doxapram</a></td><td> MAOIs enhance effects of doxapram </td><td></td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td class="cBV"><b>after stopping  MAOIs do not start duloxetine for 2 weeks, also MAOIs should not be started until at least 5 days after stopping duloxetine</b></td><td></td></tr><tr><td><a href="41001i854.htm">Entacapone</a></td><td class="cBV"><b>avoid concomitant use of non-selective  MAOIs with entacapone </b></td><td></td></tr><tr><td><a href="41001i964.htm">Escitalopram</a></td><td class="cBV"><b>after stopping  MAOIs do not start escitalopram for 2 weeks, also MAOIs should not be started until at least 1 week after stopping escitalopram</b></td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td class="cBV"><b>after stopping  MAOIs do not start fluoxetine for 2 weeks, also MAOIs should not be started until at least 5 weeks after stopping fluoxetine</b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>after stopping  MAOIs do not start fluvoxamine for 2 weeks, also MAOIs should not be started until at least 1 week after stopping fluvoxamine</b></td><td></td></tr><tr><td><a href="41001i1180.htm">Histamine</a></td><td>avoidance of  MAOIs advised by manufacturer of histamine </td><td></td></tr><tr><td><a href="41001i763.htm">Hydralazine</a></td><td>enhanced hypotensive effect when  MAOIs given with hydralazine </td><td></td></tr><tr><td><a href="41001i28.htm">Indoramin</a></td><td class="cBV"><b>avoidance of  MAOIs advised by manufacturer of indoramin </b></td><td></td></tr><tr><td><a href="41001i265.htm">Insulin</a></td><td> MAOIs enhance hypoglycaemic effect of insulin </td><td></td></tr><tr><td><a href="41001i558.htm">Levodopa</a></td><td class="cBV"><b>risk of hypertensive crisis when  MAOIs given with levodopa , avoid levodopa for at least 2 weeks after stopping MAOIs</b></td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  MAOIs given with other MAOIs (avoid for at least 2 weeks after stopping previous MAOIs and then start at a reduced dose)</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i267.htm">Metformin</a></td><td> MAOIs enhance hypoglycaemic effect of metformin </td><td></td></tr><tr><td><a href="41001i611.htm">Methyldopa</a></td><td class="cBV"><b>avoidance of  MAOIs advised by manufacturer of methyldopa </b></td><td></td></tr><tr><td><a href="41001i718.htm">Methylphenidate</a></td><td class="cBV"><b>risk of hypertensive crisis when  MAOIs given with methylphenidate , some manufacturers advise avoid methylphenidate for at least 2 weeks after stopping MAOIs</b></td><td></td></tr><tr><td><a href="41001i764.htm">Minoxidil</a></td><td>enhanced hypotensive effect when  MAOIs given with minoxidil </td><td></td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td class="cBV"><b>after stopping  MAOIs do not start mirtazapine for 2 weeks, also MAOIs should not be started until at least 2 weeks after stopping mirtazapine</b></td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  MAOIs do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i615.htm">Moxonidine</a></td><td>enhanced hypotensive effect when  MAOIs given with moxonidine </td><td></td></tr><tr><td><a href="41001i58.htm">Nefopam</a></td><td class="cBV"><b>avoidance of  MAOIs advised by manufacturer of nefopam </b></td><td></td></tr><tr><td><a href="41001i630.htm">Nicorandil</a></td><td>enhanced hypotensive effect when  MAOIs given with nicorandil </td><td></td></tr><tr><td><a href="41001i631.htm">Nitrates</a></td><td>enhanced hypotensive effect when  MAOIs given with nitrates </td><td></td></tr><tr><td><a href="41001i85.htm">Opioid Analgesics</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  MAOIs given with opioid analgesics—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs</b></td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td class="cBV"><b>after stopping  MAOIs do not start paroxetine for 2 weeks, also MAOIs should not be started until at least 1 week after stopping paroxetine</b></td><td></td></tr><tr><td><a href="41001i102.htm">Pethidine</a></td><td class="cBV"><b>CNS excitation or depression (hypertension or hypotension) when  MAOIs given with pethidine—avoid concomitant use and for 2 weeks after stopping MAOIs</b></td><td></td></tr><tr><td><a href="41001i1185.htm">Pholcodine</a></td><td>avoidance of pholcodine for 2 weeks after stopping  MAOIs advised by manufacturer of pholcodine </td><td></td></tr><tr><td><a href="41001i325.htm">Promethazine</a></td><td>avoidance of promethazine for 2 weeks after stopping  MAOIs advised by manufacturer of promethazine </td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b>risk of hypertensive crisis when  MAOIs given with rasagiline , avoid MAOIs for at least 2 weeks after stopping rasagiline</b></td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i231.htm">Reboxetine</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  MAOIs given with reboxetine (MAOIs should not be started until 1 week after stopping reboxetine, avoid reboxetine for 2 weeks after stopping MAOIs)</b></td><td></td></tr><tr><td><a href="41001i862.htm">Rizatriptan</a></td><td class="cBV"><b>risk of CNS toxicity when  MAOIs given with rizatriptan (avoid rizatriptan for 2 weeks after MAOIs)</b></td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>enhanced hypotensive effect when  MAOIs given with selegiline—manufacturer of selegiline advises avoid concomitant use</b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i237.htm">Sertraline</a></td><td class="cBV"><b>after stopping  MAOIs do not start sertraline for 2 weeks, also MAOIs should not be started until at least 1 week after stopping sertraline</b></td><td></td></tr><tr><td><a href="41001i765.htm">Sodium Nitroprusside</a></td><td>enhanced hypotensive effect when  MAOIs given with sodium nitroprusside </td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td> MAOIs enhance hypoglycaemic effect of sulfonylureas </td><td></td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>risk of CNS toxicity when  MAOIs given with sumatriptan (avoid sumatriptan for 2 weeks after MAOIs)</b></td><td></td></tr><tr><td><a href="41001i690.htm">Sympathomimetics</a></td><td class="cBV"><b>risk of hypertensive crisis when  MAOIs given with sympathomimetics </b></td><td></td></tr><tr><td><a href="41001i733.htm">Tetrabenazine</a></td><td class="cBV"><b>risk of CNS toxicity when  MAOIs given with tetrabenazine (avoid tetrabenazine for 2 weeks after MAOIs)</b></td><td></td></tr><tr><td><a href="41001i1042.htm">Tolcapone</a></td><td>avoid concomitant use of  MAOIs with tolcapone </td><td></td></tr><tr><td><a href="41001i106.htm">Tramadol</a></td><td class="cBV"><b>possible increased serotonergic effects and increased risk of convulsions when  MAOIs given with tramadol—some manufacturers advise avoid concomitant use and for 2 weeks after stopping MAOIs</b></td><td></td></tr><tr><td><a href="41001i263.htm">Tryptophan</a></td><td class="cBV"><b>CNS excitation and confusion when  MAOIs given with tryptophan (reduce dose of tryptophan)</b></td><td></td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td class="cBV"><b>enhanced CNS effects and toxicity when  MAOIs given with venlafaxine (venlafaxine should not be started until 2 weeks after stopping MAOIs, avoid MAOIs for 1 week after stopping venlafaxine)</b></td><td></td></tr><tr><td><a href="41001i575.htm">Zolmitriptan</a></td><td class="cBV"><b>increased risk of CNS toxicity when  MAOIs given with zolmitriptan </b></td><td></td></tr></tbody></table><p><b>Isocarboxazid</b> belongs to
      <b>Antidepressants</b>
          but has no specific interaction information.
        </p><p><b>Phenelzine</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i628.htm">Suxamethonium</a></td><td> phenelzine enhances effects of suxamethonium </td><td></td></tr></tbody></table><p><b>Tranylcypromine</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i427.htm">Buspirone</a></td><td>manufacturer of  tranylcypromine advises avoid buspirone for 10 days after stopping tranylcypromine</td><td></td></tr></tbody></table><p><b>MAOIs, reversible</b> belongs to
      <b>Antidepressants</b>
          but has no specific interaction information.
        </p><p><b>Moclobemide</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

























<tr><td><a href="41001i238.htm">Antidepressants, SSRI (related)</a></td><td class="cBV"><b> moclobemide should not be started for at least 1 week after stopping SSRI-related antidepressants </b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b> moclobemide should not be started for at least 1 week after stopping tricyclics </b></td><td></td></tr><tr><td><a href="41001i252.htm">Antidepressants, Tricyclic (related)</a></td><td class="cBV"><b> moclobemide should not be started for at least 1 week after stopping tricyclic-related antidepressants </b></td><td></td></tr><tr><td><a href="41001i896.htm">Bupropion</a></td><td class="cBV"><b>avoidance of  moclobemide advised by manufacturer of bupropion </b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  moclobemide increased by cimetidine (halve dose of moclobemide)</td><td></td></tr><tr><td><a href="41001i233.htm">Citalopram</a></td><td class="cBV"><b> moclobemide should not be started for at least 1 week after stopping citalopram </b></td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> moclobemide possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i882.htm">Dextromethorphan</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  moclobemide given with dextromethorphan—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td class="cBV"><b>possible increased serotonergic effects when  moclobemide given with duloxetine </b></td><td></td></tr><tr><td><a href="41001i854.htm">Entacapone</a></td><td>caution with  moclobemide advised by manufacturer of entacapone </td><td></td></tr><tr><td><a href="41001i964.htm">Escitalopram</a></td><td class="cBV"><b>increased risk of CNS toxicity when  moclobemide given with escitalopram , preferably avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td class="cBV"><b> moclobemide should not be started until 5 weeks after stopping fluoxetine </b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b> moclobemide should not be started for at least 1 week after stopping fluvoxamine </b></td><td></td></tr><tr><td><a href="41001i558.htm">Levodopa</a></td><td>increased risk of side-effects when  moclobemide given with levodopa </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> moclobemide should not be started for at least 1 week after stopping MAOIs </b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td class="cBV"><b> moclobemide should not be started for at least 1 week after stopping mirtazapine </b></td><td></td></tr><tr><td><a href="41001i85.htm">Opioid Analgesics</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  moclobemide given with opioid analgesics—manufacturer of moclobemide advises consider reducing dose of opioid analgesics</b></td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td class="cBV"><b> moclobemide should not be started for at least 1 week after stopping paroxetine </b></td><td></td></tr><tr><td><a href="41001i102.htm">Pethidine</a></td><td class="cBV"><b>possible CNS excitation or depression (hypertension or hypotension) when  moclobemide given with pethidine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i862.htm">Rizatriptan</a></td><td class="cBV"><b>risk of CNS toxicity when  moclobemide given with rizatriptan (avoid rizatriptan for 2 weeks after moclobemide)</b></td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>avoid concomitant use of  moclobemide with selegiline </b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i237.htm">Sertraline</a></td><td class="cBV"><b> moclobemide should not be started for at least 1 week after stopping sertraline </b></td><td></td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>risk of CNS toxicity when  moclobemide given with sumatriptan (avoid sumatriptan for 2 weeks after moclobemide)</b></td><td></td></tr><tr><td><a href="41001i690.htm">Sympathomimetics</a></td><td class="cBV"><b>risk of hypertensive crisis when  moclobemide given with sympathomimetics </b></td><td></td></tr><tr><td><a href="41001i575.htm">Zolmitriptan</a></td><td class="cBV"><b>risk of CNS toxicity when  moclobemide given with zolmitriptan (reduce dose of zolmitriptan)</b></td><td></td></tr></tbody></table><p><b>St John's Wort</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



















































<tr><td><a href="41001i572.htm">5HT<sub>1</sub>-receptor Agonists</a></td><td class="cBV"><b>increased serotonergic effects when  St John's wort given with 5HT<sub>1</sub> agonists—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i242.htm">Amitriptyline</a></td><td> St John's wort reduces plasma concentration of amitriptyline </td><td></td></tr><tr><td><a href="41001i470.htm">Amlodipine</a></td><td> St John's wort possibly reduces plasma concentration of amlodipine </td><td></td></tr><tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>increased serotonergic effects when  St John's wort given with SSRIs—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i276.htm">Antiepileptics</a></td><td class="cBV"><b>avoid concomitant use of  St John's wort with antiepileptics </b></td><td></td></tr><tr><td><a href="41001i1010.htm">Aprepitant</a></td><td class="cBV"><b>avoidance of  St John's wort advised by manufacturer of aprepitant </b></td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> St John's wort possibly reduces plasma concentration of aripiprazole—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of atazanavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  St John's wort advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of ciclosporin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> St John's wort reduces anticoagulant effect of coumarins (avoid concomitant use)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1120.htm">Dabigatran Etexilate</a></td><td> St John's wort possibly reduces plasma concentration of dabigatran etexilate—manufacturer of dabigatran etexilate advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of darunavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of digoxin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b> St John's wort possibly reduces plasma concentration of dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td>possible increased serotonergic effects when  St John's wort given with duloxetine </td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of efavirenz—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1205.htm">Eribulin</a></td><td> St John's wort possibly reduces plasma concentration of eribulin </td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td>avoidance of  St John's wort advised by manufacturer of etravirine </td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td> St John's wort possibly reduces plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of fosamprenavir—avoid concomitant use</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i1170.htm">Gefitinib</a></td><td>avoidance of  St John's wort advised by manufacturer of gefitinib </td><td></td></tr><tr><td><a href="41001i933.htm">Imatinib</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of imatinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of indinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1006.htm">Irinotecan</a></td><td class="cBV"><b> St John's wort accelerates metabolism of irinotecan (reduced plasma  concentration—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td> St John's wort reduces plasma concentration of ivabradine—avoid concomitant use</td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  St John's wort advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of lopinavir—avoid concomitant use</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> St John's wort possibly reduces plasma concentration of maraviroc—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> St John's wort possibly reduces plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td> St John's wort possibly reduces plasma concentration of <i>oral</i> midazolam </td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of nelfinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of nevirapine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i475.htm">Nifedipine</a></td><td> St John's wort reduces plasma concentration of nifedipine </td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td class="cBV"><b> St John's wort reduces contraceptive effect of oestrogens (avoid concomitant use)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td> St John's wort possibly reduces plasma concentration of omeprazole </td><td></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td class="cBV"><b> St John's wort reduces contraceptive effect of progestogens (avoid concomitant use)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of ritonavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td> St John's wort reduces plasma concentration of simvastatin </td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of tacrolimus—avoid concomitant use</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>avoidance of  St John's wort advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of telithromycin (avoid during and for 2 weeks after St John's wort)</b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of theophylline—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b> St John's wort possibly reduces plasma concentration of tipranavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1163.htm">Ulipristal</a></td><td class="cBV"><b>avoidance of  St John's wort advised by manufacturer of ulipristal (contraceptive effect of ulipristal possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td>possible increased serotonergic effects when  St John's wort given with venlafaxine </td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b> St John's wort significantly reduces plasma concentration of verapamil </b></td><td></td></tr><tr><td><a href="41001i1181.htm">Vinflunine</a></td><td class="cBV"><b> St John's wort possibly reduces plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b> St John's wort reduces plasma concentration of voriconazole—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Tryptophan</b> belongs to
      <b>Antidepressants</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>agitation and nausea may occur when  tryptophan given with SSRIs </b></td><td></td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td>possible increased serotonergic effects when  tryptophan given with duloxetine </td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td>CNS toxicity reported when  tryptophan given with fluoxetine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>CNS excitation and confusion when  tryptophan given with MAOIs (reduce dose of tryptophan)</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1145.htm" title="Agomelatine">Agomelatine</a></li><li><a href="41001i823.htm" title="Mirtazapine">Mirtazapine</a></li><li id="_41001i230"><a href="41001i230.htm" title="Antidepressants, Noradrenaline Re-uptake Inhibitors">Antidepressants, Noradrenaline Re-uptake Inhibitors</a></li><li id="_41001i232"><a href="41001i232.htm" title="Antidepressants, SSRI">Antidepressants, SSRI</a></li><li id="_41001i238"><a href="41001i238.htm" title="Antidepressants, SSRI (related)">Antidepressants, SSRI (related)</a></li><li id="_41001i241"><a href="41001i241.htm" title="Antidepressants, Tricyclic">Antidepressants, Tricyclic</a></li><li id="_41001i252"><a href="41001i252.htm" title="Antidepressants, Tricyclic (related)">Antidepressants, Tricyclic (related)</a></li><li id="_41001i257"><a href="41001i257.htm" title="MAOIs">MAOIs</a></li><li id="_41001i261"><a href="41001i261.htm" title="MAOIs, reversible">MAOIs, reversible</a></li><li><a href="41001i905.htm" title="St John's Wort">St John's Wort</a></li><li><a href="41001i263.htm" title="Tryptophan">Tryptophan</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i228.htm">Previous: Tinzaparin</a> | <a class="top" href="41001i229.htm#">Top</a> | <a accesskey="]" href="41001i1145.htm">Next: Agomelatine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>